麻豆传媒

John Gever

John Gever

Authors >

John Gever

John has decades of experience in medical, science, and business journalism. He holds a bachelor's degree from the University of Michigan (physics and astronomy) and a master's from Boston University (science communication). He freelanced for many years before joining 麻豆传媒, writing for the medical industry trade press and community newspapers and magazines. He has also worked in university communications for institutions in Alabama and New Hampshire.

Connect:

email image

Latest from John Gever

A close up photo of broccoli soup.

Really, Soup Might Help in Osteoarthritis?

Not just any soup. And no chicken needed.

A photo of a prescription bottle of metformin tablets next to a glucose monitor.

Lupus Complications Reduced With Common Diabetes Drug

Metformin benefits seen extending way beyond its glucose-lowering properties

A computer rendering of test tubes of blood lying on a test form.

Use This Common Cardiac Test in RA Patients, Study Suggests

Identifies heart risks not captured by conventional risk factors

EULAR over a photo of Vienna Exhibition Center in Vienna, Austria.

SpA Patients Do Just Fine Managing Their Own Follow-Up Care

Randomized trial suggests usual practice is wasteful

EULAR over a photo of Vienna Exhibition Center in Vienna, Austria.

Izokibep Marches on for Psoriatic Arthritis

Early phase III data cement case for novel IL-17A inhibitor

EULAR over a photo of Vienna Exhibition Center in Vienna, Austria.

Novel URAT1 Inhibitors Advance for Gout

New treatment options on the horizon come into better focus

EULAR over a photo of Vienna Exhibition Center in Vienna, Austria.

OA Patients Get Long-Term Benefit From Lifestyle Improvements

Improvement in pain and function lasted well after formal program ended

EULAR over a photo of Vienna Exhibition Center in Vienna, Austria.

Is 'Difficult-to-Treat' RA a Lost Cause?

The name says it all, but progress appears to be coming

EULAR over a photo of Vienna Exhibition Center in Vienna, Austria.

CAR-T Treatment Continues to Astonish in Rheumatologic Diseases

Numbers of patients, length of follow-up keep growing with no visible downside (yet)

A close up photo of a Humira prefilled syringe.

Humira Clobbers Biosimilars in Battle for Part D Coverage

Pricing, payer policies keep market leader on top

5

鈥�